XTL Biopharmaceuticals Ltd. (XTLB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

XTL Biopharmaceuticals Ltd. (XTLB) closed at USD 1.88 on 2026-10-14, a change of -59.8 % over the past year, with a market capitalization of USD 4.69M.

XTL Biopharmaceuticals Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

XTL Biopharmaceuticals Ltd. key figures

Previous close

USD 1.88 (2026-10-14)

1-year change

-59.8 %

Market cap

USD 4.69M

Enterprise value

USD 4.62M

P/E ratio (trailing)

-5.62

P/E ratio (forward)

n/a

EPS (trailing)

-0.34

EPS (forward)

n/a

PEG ratio

2.27

Price to book

n/a

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.13

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for XTL Biopharmaceuticals Ltd. and compare it with other stocks.